UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R)

Viruses, 2022-07, Vol.14 (7), p.1541

2022

Volltextzugriff (PDF)

Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral treatment

Journal of viral hepatitis, 2019-02, Vol.26 (2), p.224-230

2019

Volltextzugriff (PDF)

Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C—Results from the German Hepatitis C-Registry (DHC-R)

Biomedicines, 2021-10, Vol.9 (10), p.1495

2021

Volltextzugriff (PDF)

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study

Journal of hepatology, 2017-11, Vol.67 (5), p.918-924

2017

Volltextzugriff (PDF)

Veränderungen der Hepatitis-C-Virus-Genotyp-1a/1b-Verteilung zwischen 2004 und 2018 in Deutschland – eine Analyse von 17093 Patienten aus verschiedenen Real-World-Registern

Zeitschrift für Gastroenterologie, 2021-03, Vol.59 (3), p.241-249

2021

Volltextzugriff (PDF)

HCV-Therapie – Die unterschiedliche Preisentwicklung in Europa

Zeitschrift für Gastroenterologie, 2016-07, Vol.54 (7), p.701-702

2016

Volltextzugriff (PDF)

Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon Era

Clinical infectious diseases, 2020-08, Vol.71 (5), p.1248-1254

2020

Volltextzugriff (PDF)

Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C

Journal of hepatology, 2018-04, Vol.68 (4), p.663-671

2018

Volltextzugriff (PDF)

Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV–Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01)

Clinical infectious diseases, 2016-11, Vol.63 (10), p.1320-1324

2016

Volltextzugriff (PDF)

Deutsches Hepatitis C-Register (DHC-R) – eine Zwischenbilanz 4 Jahre nach Zulassung direkt antiviraler Substanzen (DAAs)

Zeitschrift für Gastroenterologie, 2019-01, Vol.57 (1), p.27-36

2019

Volltextzugriff (PDF)

Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry

European journal of gastroenterology & hepatology, 2021-03, Vol.33 (3), p.415-423

2021

Volltextzugriff (PDF)

Has Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany?

Journal of clinical gastroenterology, 2020-02, Vol.54 (2), p.192-199

2020

Volltextzugriff (PDF)

Aktuelle Empfehlung zur Therapie der chronischen Hepatitis C

Zeitschrift für Gastroenterologie, 2014-10, Vol.52 (10), p.1185-1197

2014

Volltextzugriff (PDF)

Late presentation of chronic hepatitis C patients in the era of direct‐acting antivirals—Data from the German Hepatitis C‐Registry

Journal of viral hepatitis, 2021-11, Vol.28 (11), p.1660-1664

2021

Volltextzugriff (PDF)

Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R)

Zeitschrift fur Gastroenterologie, 2020-09, Vol.58 (9), p.841-846

2020

Volltextzugriff (PDF)

Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy – data from the German hepatitis C registry (DHC-R)

Zeitschrift für Gastroenterologie, 2020-04, Vol.58 (4), p.341-351

2020

Volltextzugriff (PDF)

Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry

Drugs & aging, 2018-09, Vol.35 (9), p.843-857

2018

Volltextzugriff (PDF)

Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015

Zeitschrift fur Gastroenterologie, 2019-05, Vol.57 (5), p.584-592

2019

Volltextzugriff (PDF)

Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry

European journal of gastroenterology & hepatology, 2019-02, Vol.31 (2), p.230-240

2019

Volltextzugriff (PDF)

Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry

Hepatology communications, 2022-09, Vol.6 (9), p.2488-2495

2022

Volltextzugriff (PDF)

Real-world data on long-term quality of life after Glecaprevir/Pibrentasvir therapy: data from the German hepatitis C registry (DHC-R)

Journal of hepatology, 2023-06, Vol.78, p.S1186

2023

Volltextzugriff (PDF)

THU-181 - Real-world data on long-term quality of life after Glecaprevir/Pibrentasvir therapy: data from the German hepatitis C registry (DHC-R)

Journal of hepatology, 2023-06, Vol.78, p.S1186-S1186

2023

Volltextzugriff (PDF)

Sicherheit vor Regressen – Wirtschaftlichkeit in der Verordnung der Hepatitis C-Therapie

Zeitschrift für Gastroenterologie, 2015-07, Vol.53 (7), p.742-745

2015

Volltextzugriff (PDF)

1 – 25 von 76

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(52)

Publikationsform

Sprache

Englisch
(63)
Deutsch
(18)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R)

Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral treatment

Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C—Results from the German Hepatitis C-Registry (DHC-R)

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study

Veränderungen der Hepatitis-C-Virus-Genotyp-1a/1b-Verteilung zwischen 2004 und 2018 in Deutschland – eine Analyse von 17093 Patienten aus verschiedenen Real-World-Registern

HCV-Therapie – Die unterschiedliche Preisentwicklung in Europa

Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon Era

Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C

A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B

Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV–Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01)

Deutsches Hepatitis C-Register (DHC-R) – eine Zwischenbilanz 4 Jahre nach Zulassung direkt antiviraler Substanzen (DAAs)

Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry

Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral therapy—Results from the German Hepatitis C‐Registry

Has Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany?

Aktuelle Empfehlung zur Therapie der chronischen Hepatitis C

Late presentation of chronic hepatitis C patients in the era of direct‐acting antivirals—Data from the German Hepatitis C‐Registry

Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R)

Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy – data from the German hepatitis C registry (DHC-R)

Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry

Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015

Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry

Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry

Real-world data on long-term quality of life after Glecaprevir/Pibrentasvir therapy: data from the German hepatitis C registry (DHC-R)

THU-181 - Real-world data on long-term quality of life after Glecaprevir/Pibrentasvir therapy: data from the German hepatitis C registry (DHC-R)

Sicherheit vor Regressen – Wirtschaftlichkeit in der Verordnung der Hepatitis C-Therapie

Aktive Filter

Suchergebnisse filtern